Since sorafenib is already an FDA-approved therapy for hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer [10,11,12] with a well-characterized safety profile, it could readily be repurposed as a targeted therapy in the specific lung cancer subgroup harboring the ARAF p.S214C mutation without the need for the extensive safety trials typically required for novel drugs. This evidence concerns the gene ARAF and hereditary clear cell renal cell carcinoma.